Fig. 1: Treatment timeline during induction therapy and subsequent surgery. | npj Precision Oncology

Fig. 1: Treatment timeline during induction therapy and subsequent surgery.

From: Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation

Fig. 1

A Positron emission tomography/computed tomography (PET/CT) scan reveals a mass in the right lower lobe, along with enlarged hilar and mediastinal lymph nodes, and FDG uptake in the right supraclavicular lymph node. B Next-generation sequencing (NGS) identifies an ERBB2 p.Y772-A775dupYNMA mutation (43.81% VAF). Immunohistochemical analysis shows PD-L1 expression (22C3, TPS 50%). C CT images after one cycle of induction therapy demonstrate a reduction in the size of the tumor lesion. D CT images after three cycles of induction therapy show a further reduction in tumor size, with slight interstitial lung disease (Grade 1). Significant remission is observed after a 10-day course of dexamethasone. E PET/CT scan shows shrinkage of the tumor lesion and decreased FDG uptake in the right supraclavicular lymph node.

Back to article page